Context Therapeutics Inc.
CNTX
$1.52
-$0.19-11.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 18.56% | 4.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -32.31% | 30.10% | |||
| Operating Income | 32.31% | -30.10% | |||
| Income Before Tax | 33.36% | -34.38% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 33.36% | -34.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 33.36% | -34.38% | |||
| EBIT | 32.31% | -30.10% | |||
| EBITDA | 32.33% | -30.12% | |||
| EPS Basic | 33.33% | -34.38% | |||
| Normalized Basic EPS | 33.33% | -34.43% | |||
| EPS Diluted | 33.33% | -34.38% | |||
| Normalized Diluted EPS | 33.33% | -34.43% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||